These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 30267200)

  • 1. Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma.
    Tzeng A; Diaz-Montero CM; Rayman PA; Kim JS; Pavicic PG; Finke JH; Barata PC; Lamenza M; Devonshire S; Schach K; Emamekhoo H; Ernstoff MS; Hoimes CJ; Rini BI; Garcia JA; Gilligan TD; Ornstein MC; Grivas P
    Target Oncol; 2018 Oct; 13(5):599-609. PubMed ID: 30267200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy.
    Ornstein MC; Diaz-Montero CM; Rayman P; Elson P; Haywood S; Finke JH; Kim JS; Pavicic PG; Lamenza M; Devonshire S; Dann P; Schach K; Stephenson A; Campbell S; Emamekhoo H; Ernstoff MS; Hoimes CJ; Gilligan TD; Rini BI; Garcia JA; Grivas P
    Urol Oncol; 2018 Sep; 36(9):405-412. PubMed ID: 29606341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma.
    Sheng IY; Diaz-Montero CM; Rayman P; Wei W; Finke JH; Kim JS; Pavicic PG; Lamenza M; Company D; Stephenson A; Campbell S; Haber G; Lee B; Mian O; Gilligan TD; Rini BI; Garcia JA; Grivas P; Ornstein MC
    Target Oncol; 2020 Apr; 15(2):211-220. PubMed ID: 32207064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Immune Checkpoint Blockade on Myeloid-Derived Suppressor Cell Populations in Patients With Melanoma.
    Sun SH; Benner B; Savardekar H; Lapurga G; Good L; Abood D; Nagle E; Duggan M; Stiff A; DiVincenzo MJ; Suarez-Kelly LP; Campbell A; Yu L; Wesolowski R; Howard H; Shah H; Kendra K; Carson WE
    Front Immunol; 2021; 12():740890. PubMed ID: 34712230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab for the treatment of urothelial cancers.
    Teo MY; Rosenberg JE
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):215-221. PubMed ID: 29363363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival.
    Fallah J; Diaz-Montero CM; Rayman P; Wei W; Finke JH; Kim JS; Pavicic PG; Lamenza M; Dann P; Company D; Stephenson A; Campbell S; Haber G; Lee B; Mian O; Gilligan T; Garcia JA; Rini B; Ornstein MC; Grivas P
    Clin Genitourin Cancer; 2020 Dec; 18(6):500-508. PubMed ID: 32340875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-Derived Suppressor Cell Subset Accumulation in Renal Cell Carcinoma Parenchyma Is Associated with Intratumoral Expression of IL1β, IL8, CXCL5, and Mip-1α.
    Najjar YG; Rayman P; Jia X; Pavicic PG; Rini BI; Tannenbaum C; Ko J; Haywood S; Cohen P; Hamilton T; Diaz-Montero CM; Finke J
    Clin Cancer Res; 2017 May; 23(9):2346-2355. PubMed ID: 27799249
    [No Abstract]   [Full Text] [Related]  

  • 8. Circulating Myeloid-Derived Suppressor Cell Subsets in Patients with Colorectal Cancer - Exploratory Analysis of Their Biomarker Potential.
    Fědorová L; Pilátová K; Selingerová I; Bencsiková B; Budinská E; Zwinsová B; Brychtová V; Langrová M; Šefr R; Valík D; Zdražilová Dubská L
    Klin Onkol; 2018; 31(Suppl 2):88-92. PubMed ID: 31023030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
    Mogenet A; Finetti P; Denicolai E; Greillier L; Boudou-Rouquette P; Goldwasser F; Lumet G; Ceccarelli M; Birnbaum D; Bedognetti D; Mamessier E; Barlesi F; Bertucci F; Tomasini P
    J Transl Med; 2023 Sep; 21(1):637. PubMed ID: 37726776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating T Cell Subpopulations Correlate With Immune Responses at the Tumor Site and Clinical Response to PD1 Inhibition in Non-Small Cell Lung Cancer.
    Manjarrez-Orduño N; Menard LC; Kansal S; Fischer P; Kakrecha B; Jiang C; Cunningham M; Greenawalt D; Patel V; Yang M; Golhar R; Carman JA; Lezhnin S; Dai H; Kayne PS; Suchard SJ; Bernstein SH; Nadler SG
    Front Immunol; 2018; 9():1613. PubMed ID: 30123214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DC-HIL/Gpnmb Is a Negative Regulator of Tumor Response to Immune Checkpoint Inhibitors.
    Chung JS; Ramani V; Kobayashi M; Fattah F; Popat V; Zhang S; Cruz PD; Gerber DE; Ariizumi K
    Clin Cancer Res; 2020 Mar; 26(6):1449-1459. PubMed ID: 31822499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myeloid-derived suppressor cells in peripheral blood as predictive biomarkers in patients with solid tumors undergoing immune checkpoint therapy: systematic review and meta-analysis.
    Möller M; Orth V; Umansky V; Hetjens S; Braun V; Reißfelder C; Hardt J; Seyfried S
    Front Immunol; 2024; 15():1403771. PubMed ID: 38855104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.
    Mundy-Bosse BL; Young GS; Bauer T; Binkley E; Bloomston M; Bill MA; Bekaii-Saab T; Carson WE; Lesinski GB
    Cancer Immunol Immunother; 2011 Sep; 60(9):1269-79. PubMed ID: 21604071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment.
    Wang YL; Gong Y; Lv Z; Li L; Yuan Y
    J Cancer; 2021; 12(6):1698-1707. PubMed ID: 33613757
    [No Abstract]   [Full Text] [Related]  

  • 15. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer.
    Stenehjem DD; Tran D; Nkrumah MA; Gupta S
    Onco Targets Ther; 2018; 11():5973-5989. PubMed ID: 30275703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-Derived Suppressor Cells as an Immune Parameter in Patients with Concurrent Sunitinib and Stereotactic Body Radiotherapy.
    Chen HM; Ma G; Gildener-Leapman N; Eisenstein S; Coakley BA; Ozao J; Mandeli J; Divino C; Schwartz M; Sung M; Ferris R; Kao J; Wang LH; Pan PY; Ko EC; Chen SH
    Clin Cancer Res; 2015 Sep; 21(18):4073-4085. PubMed ID: 25922428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and Predictive Value of Tumor-infiltrating Leukocytes and of Immune Checkpoint Molecules PD1 and PDL1 in Clear Cell Renal Cell Carcinoma.
    Stenzel PJ; Schindeldecker M; Tagscherer KE; Foersch S; Herpel E; Hohenfellner M; Hatiboglu G; Alt J; Thomas C; Haferkamp A; Roth W; Macher-Goeppinger S
    Transl Oncol; 2020 Feb; 13(2):336-345. PubMed ID: 31881506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study).
    Bersanelli M; Buti S; Cortellini A; Bandini M; Banna GL; Pederzoli F; Farè E; Raggi D; Giannatempo P; De Giorgi U; Basso U; Losanno T; Santini D; Mucciarini C; Tucci M; Tambaro R; Farnesi A; Caffo O; Veccia A; Naglieri E; Briganti A; Procopio G; Pignata S; Necchi A
    Clin Med Insights Oncol; 2021; 15():11795549211021667. PubMed ID: 34290538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures.
    Hossain SM; Gimenez G; Stockwell PA; Tsai P; Print CG; Rys J; Cybulska-Stopa B; Ratajska M; Harazin-Lechowska A; Almomani S; Jackson C; Chatterjee A; Eccles MR
    Front Immunol; 2022; 13():955063. PubMed ID: 36248850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.